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Low Accuracy of Tumor Markers for Diagnosing
Pancreatic Neuroendocrine Tumors in Multiple
Endocrine Neoplasia Type 1 Patients
Joanne M. de Laat, Carolina R. C. Pieterman, Maaike Weijmans, Ad R. Hermus,
Olaf M. Dekkers, Wouter W. de Herder, Anouk N. A. van der Horst-Schrivers,
Madeleine L. Drent, Peter H. Bisschop, Bas Havekes, Menno R. Vriens,
and Gerlof D. Valk*
Context: The assessment of tumor markers for diagnosing pancreatic neuroendocrine tumors
(pNET) in multiple endocrine neoplasia type 1 (MEN1) patients is advised in the current guidelines
but has never been validated for this purpose.
Objective: The objective of the study was to assess the diagnostic accuracy of chromogranin A
(CgA), pancreatic polypeptide (PP), and glucagon for pNET in MEN1.
Design: This was a diagnostic study.
Setting: The study was conducted at Dutch university medical centers from 2008 to 2011, repre-
senting 90% of the total Dutch MEN1 population.
Patients and Methods: Patients for whom data on tumor markers in combination with the refer-
ence standard (ie, radiological imaging)wereavailablebetween2008and2011were included. The
reference standard for the presence of pNET was pathology or detection on magnetic resonance
imaging, computed tomography, or endoscopic ultrasound confirmed on subsequent imaging,
irrespective of modality at follow-up.
Main Outcome Measures: The area under the receiver-operating characteristic curve (AUC), pos-
itivepredictive value, negativepredictive value, positive likelihood ratio, negative likelihood ratio,
sensitivity, and specificity were calculated for each marker.
Results: For the analysis of PP, CgA, and glucagon, 73, 81, and 94 patients were available, respec-
tively. TheAUC forCgAwas0.48 [95%confidence interval (CI) 0.35–0.61]with a sensitivity 0.33 and
a specificity 0.73; the AUC for glucagon was 0.58 (95% CI 0.46–0.70) with a sensitivity 0.43 and a
specificity 0.73; and the AUC for PP was 0.64 (95% CI 0.50–0.77) with a sensitivity 0.36 and a
specificity 0.74. Age, imaging modality, tumor size, and number did not influence the outcomes.
Conclusion:Thediagnostic accuracyof the tumormarkers CgA, PP, andglucagon forpNET inMEN1
is low. (J Clin Endocrinol Metab 98: 4143–4151, 2013)
Multiple endocrine neoplasia type 1 (MEN1) is a rareautosomal dominant inherited disorder that is
caused by mutations in the MEN1 gene on chromosome
11 (1). MEN1 causes combinations of more than 20 dif-
ferent endocrine and nonendocrine tumors (2). The main
endocrine manifestations of MEN1 are parathyroid hy-
perplasia or adenomas (occurring in 78%–94% of pa-
tients with MEN1); neuroendocrine tumors (NET) of the
pancreas (pNET) or duodenum (35%–75%); adrenal ad-
enomas and adrenal nodular hyperplasia (27%–73%);
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anterior pituitary tumors (20%–65%); and gastric, thy-
mic, or lung NETs (8%) (3, 4). Signs and symptoms are a
consequence of hormone overproduction, local mass ef-
fects, or malignancy (5). Most MEN1-associated tumors
are benign, but pancreatic and thymic NETs especially
show malignant behavior. Therefore, MEN1 patients
have a shorter life expectancy than the general population
with a 20-year survival of patients affectedwithMEN1 of
64% (6). However, among two families in northern Fin-
land with a founder MEN1 mutation, the mean age of
death for MEN1-affected patients and their spouses did
not significantly differ (7).
Today MEN1-related mortality is most frequently
caused by pNET and thymic NET (8). For pNET, screen-
ing and subsequent treatment in asymptomaticMEN1pa-
tients seems to lead to a more favorable survival and a
decreased morbidity (5, 9).
The current standard of care for MEN1 patients is
based on the recently updated clinical practice guidelines
for MEN1 (2, 10). The biochemical tests recommended
for early diagnosing of pNET include the annual assess-
ment of chromogranin A (CgA), pancreatic polypeptide
(PP), and glucagon.
Data on the diagnostic accuracy of the tumor markers
for diagnosing pNET inMEN1patients is scarce. Elevated
levels of CgA seemed to be specific for identifying neu-
roendocrine tumors when patients without MEN1 were
compared with healthy controls, but sensitivity was vari-
able (11, 12). Some studies have suggested that levels of
CgAmight be elevated inMEN1patients in the absence of
active disease (13–15).
To achieve an effective screening program for MEN1
carriers, more information is needed about the diagnostic
value of these biochemical tests. Therefore, the aim of the
present study was to assess the accuracy of the already
often usedCgA, glucagon, and PP for diagnosing pNET in
the periodic follow-up of MEN1 patients.
Materials and Methods
The present study was based on data from the national MEN1
database of theDutchMEN1 StudyGroup (DMSG). The database
comprises90%of the totalDutchMEN1population (16)ofwhom
theavailable clinical dataof everyquarterper yearwas collected for
the period 1990 up to 2011. Data collection was performed for
every quarter using a predefined protocol and decision rules for
registration of data. The database was designed to assess the effec-
tiveness of the current practice of care for patients withMEN1. In
each center, MEN1 patients were identified by a standard identifi-
cationprocedureusing thehospitaldatabasesofmedical conditions
and diseases. All patientswithMEN1aged 16 years or older by the
end of 2010 who were treated at one of the university medical
centers (UMCs)were included.MEN1wasdiagnosed according to
the recently updated clinical practice guidelines (2). The study pro-
tocolwasapprovedbytheMedicalEthicalCommitteesofallUMCs
in The Netherlands. Given the retrospective and observational na-
ture of the study, theMedical EthicalCommittees approved the use
of these clinical data for study aims andwaived the requirement to
obtain informed consent. The data were collected after the study
questions were formulated and the potential variables of interest
were identified.
Patient selection
In the present analyses, patients under care between2008 and
2011 (n 274) were eligible. This period was chosen to be able
to study the currently used andmost up-to-date biochemical and
radiological tests.
Patients were included in the analyses if the presence or ab-
sence of pNET could be assessed according to the reference stan-
dard described below. Patients were excluded from the analyses
if laboratory results of interest were not measured within 3
months before or after assessing the reference standard.
Increased levels ofCgA can also be caused by otherNETs (17,
18). For this reason additional selection criteria were applied in
the analysis of CgA. First, patients with simultaneous thymic,
lung, or gastric NET were excluded. Because patients with gas-
trinomas, and especially those with Zollinger Ellison syndrome,
are currently treated with proton pump inhibitor (PPI), we per-
formed an additional subgroup analysis for PPI use in the anal-
ysis of CgA.
Patients with missing data were excluded per analysis.
Outcome measures
The reference standard for the presence of pNET was the
outcomeof a pathology examination. If pathologywasnot avail-
able, only pNET diagnosed on magnetic resonance imaging
(MRI), computed tomography (CT), or endoscopic ultrasound
(EUS), which were confirmed at least once by consecutive im-
aging studies, irrespective of imaging modality, were considered
as pNETpositive.The absenceof pNETalsohad tobe confirmed
on a minimum of two subsequent imaging studies during
follow-up.
Primary outcomes were the accuracy of PP, glucagon, and
CgA for diagnosing pNET according to the reference standard.
Secondaryoutcomeswere thediagnostic accuracyof the com-
bined tumor makers for pNET and diagnostic accuracy for met-
astatic disease. The reference standard formetastatic diseasewas
defined as metastases confirmed in pathological examination
(metastases in liver, lymphnodes, andperitoneum)ormetastases
identified on abdominal MRI, CT, or EUS examination (metas-
tases in liver, lymph nodes, bones, peritoneum).
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Additionally, we assessed the association of tumor markers
with age, tumor size, and number of tumors. Furthermore, we
analyzed the diagnostic value for the different imaging modali-
ties and the available data on octreoscans and EUS with fine-
needle aspiration (FNA). Because of the interactionbetweenPPIs
and CgA, all analyses of CgA were categorized for PPI use (19).
For the analysisweused the standardupper limits of reference
values for the tumor markers as currently used in clinical prac-
tice. Although previous studies have reported some age-depen-
dent regression for PP, generally no correction for this regression
is performed indaily clinical practice (20).Additionally, to assess
whether a significant influence of age on the results exists, we
performed a sensitivity analysis using age-adjusted reference val-
ues for tumormarkers that hada significant correlationwith age.
Tumor markers
All laboratory results analyzed were obtained from tumor
marker assessments performed in the course of patient care be-
tween 2008 and 2011. Tumor marker assessments were per-
formed centralized in a small number of laboratories. PP analysis
wasperformed inone center using aRIA fromEuro-Diagnostica.
Long-term assay stability was measured using patients pools at
three levels, viz, at 27, 92, and 170 pmol/L. These patient pools
were used from 2008 until 2011.Three antibody kits were used
between2008and2011. Interassay variationwas10%,6%, and
6% for these three kits. Cross-reactivity for insulin, glucagon,
gastrin-34. and gastrin-17 is less than 0.03%.
TheCgA assayswere performed in two centers both using the
Cis Bio immunoradiometric assay with identical reference val-
ues. Interassay variation was 9%, 10%, and 6% at 34, 72, and
271g/L. Both laboratories used patient pools at three levels for
the long-term control during the study period. Each batch of
pools was used for about 1 year. Five lot numbers of reagents for
CgA analysis were used.
Glucagon assays were performed in four laboratories using a
RIA from SiemensHealthcare Diagnostics or LincoDiagnostics.
It is standardized against World Health Organization Interna-
tional Standard 69/194 (21). Interassay variation was 12%,
12%, and 7% at 16, 23, and 40 pmol/L. Centers did not use
patient pools during the whole study period. However, all lab-
oratories report that the overall interassay coefficient of varia-
tion was less than 10% over the time a batch of control samples
was used. No systematic decrease or increase was seen in that
time. Cross-reactivity for glucagon 22–29 is 5%–10% and for
glucagon 19–29 it is 2.3–4.7% (information from manufac-
turer). PPs are represented in picomoles per liter andCgA tests in
micrograms per liter. The laboratories of the UMCs reported the
levels of glucagon in different units, respectively, nanograms per
liter and picomoles per liter. For the analyses, the measure pi-
comoles per liter was converted to nanograms per liter (1 ng/L
0.2872 pmol/L). All four laboratories used identical reference
values for glucagon, and therefore, no standardization of tumor
marker values was needed.
Currently used upper limits of reference values are for PP 100
pmol/L, for glucagon 80 ng/L, and forCgA100g/L as provided
by themanufacturer of the diagnostic kits and based on previous
studies (12, 14, 17, 20).
Statistical analysis
Diagnostic accuracy was assessed using receiver operating
characteristics (ROC) curves. The area under the ROC curves
(AUC) were calculated with an AUC of 0.60–0.80 indicating
moderate, and 0.80–1.00 indicating good diagnostic accuracy.
The current reference values of the tumor markers were used as
cutoff for the three tumor markers. For the analysis of the com-
bined tumor markers, the tumor markers were considered pos-
itive if one or more tumor makers were elevated. We also in-
tended to calculate the optimal cutoff using the ROC curves for
tumor markers with an AUC above 0.8.
Diagnostic accuracy with age-adjusted reference values was
obtained first by calculating the difference between the observed
tumor maker value and the predicted tumor marker value. Sec-
ond, the AUC was calculated for sensitivity (Se) and specificity
(Sp) using the following formulas: Se  true positive/(true pos-
itive  false negative) and Sp  true negative/(true negative 
false positive). The positive (PPV) and negative predictive value
(NPV)were calculated using the following formulas: PPV true
positive/(true positive  false positive); NPV  true negative/
(true negative false negative). The positive (LR) and negative
(LR) likelihood ratios were calculated using the following for-
mulae: LR  sensitivity/(1  specificity), LR  (1  sensi-
tivity)/specificity. In addition, exact 95% confidence intervals
(CIs) of the predictive values and likelihood ratios were calcu-
lated according to the methods described by Altman (22). Scat-
terplots were made to assess the observed results of tumor
marker levels for individual patients. The association of tumor
makerswith age, tumor size, and number of tumorswas assessed
by subgroup analyses and by linear regression. For subgroup
analyses, categorizations of data for pNET size, pNET number,
and age were based on the median (data ormedian). Linear
regression was applied to logistically transformed data of tumor
makers, age, tumor size, and number of tumors to diminish the
impact of extreme values. Regression coefficients with P  .05
were considered significant.
To assess whether age-adjusted reference values would influ-
ence study results, we performed a sensitivity analysis based on
age-adjusted reference values. Reference values were internally
adjusted for age using linear regression by calculating the dif-
ference between the standard reference value and the calculated
age adjusted tumormarker value according to theoutcomeof the
regression analyses of tumormarkers and age. In addition, types
of imaging test (CT,MRI, or EUS)were separately analyzed, and
forCgA, a stratified analysis forPPIusewasperformed.Analyses
were conducted using SPSS 17.0 and R version 2.9.2.
Results
Study population
Of the total of274eligibleMEN1patients, 159patients
were included (Figure 1). Seventy-three, 81, and 94 of
those 159 patients were available for analysis of PP, CgA,
and glucagon, respectively. In 50 patients all three tumor
markers were assessed. Median age of the patients at the
baseline assessment was 44 years (range 16–78 years).
There were more females than males (94 females and 65
males). Age and gender of the excluded and included pa-
tients were not statistically different.
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Tumor markers for diagnosing pNET
The AUCs of CgA, PP, and glucagon were small for all
tumormarkers. For patients not using PPI, the AUC of CgA
was also low [0.56 (95% CI 0.41–0.70)].
The outcomes of the Se, Sp, LR, LR, andAUCs are listed
inTable1.Thediagnosticaccuracywascomparablewhenan
optimal cutoff point for these data was used.
Figure 2 represents theAUCs and the scatterplots of the
outcomes of the tumormarkers in individual patientswith
and without pNET according to the reference standard.
The analysis of the combined tu-
mor marker CgA, PP, and glucagon
was based on all 159 patients. The
AUC was 0.59 (95% CI 0.50–0.68)
with a LR of 1.50 (95% CI 1.01–
2.22) and a LR of 0.74 (95% CI
0.59–0.92).A total of 27patients had
elevated tumormarkers in the absence
of pNETon imaging. In those patients
the mean time between first and last
imagingwas 2 years and amean num-
ber of 3.2 additional imaging studies
was performed per patient, confirm-
ing the negative outcome of the refer-
ence standard.
Tumor markers for metastatic
disease
The Se, Sp, LR, LR, and AUCs
of the individual tumormarkers fordi-
agnosing metastatic disease are presented in Table 2. The
prevalence of metastatic disease in the population ranged
from 7% to 12% in separate analyses, depending on the
number of patients included. The LR ranged from 1.50 to
1.89 and LR from 0.66 to 0.75.
Factors influencing diagnostic accuracy
Correlations between the level of the tumor markers
and tumor size, number, or age were weak, with R2 rang-
ing between less than0.001 and0.061 (Figure 3). The only
 
CgA: chromogranin A 
PP: pancreatic polypeptide 
NET: neuroendocrine tumor 
PPI: proton pump inhibitors 
n: number of patients 
274 Eligible MEN1 Patients 
159 Included Patients 
Excluded (n=115)  
- no reference standard (n=63),  
- no matching laboratory results 
(n=50) 
- disconcordant outcomes of 
imaging studies (n=2) 




- subgroup with PPI (n=20) 
- subgroup without PPI (n=61) 
All three markers (n=50) 
Figure 1. Flow chart of patient enrolled in the study for diagnostic accuracy of tumor markers
for pNET.
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LR 0.83 (0.70–0.98)
0.56 (0.41–0.70)


























































Abbreviation: n.d., not determined.
a With 95% CI.
b In the CgA analyses patients with lung, thymic, and gastric NET were excluded.
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significant correlation foundwas betweenPP andage (P
.036). Adjusting for age did not improve diagnostic accu-
racy of PP (AUC 0.57 95% CI 0.43–0.71). An additional
categorized analysis also showed no significant difference
in theAUCof tumormarkerswith tumor size, tumornum-
ber, or age (Table 3).
The accuracyof the tumormarkerswasnot influencedby
type of imaging used (CT, MRI, or EUS) (Table 4). There
were no statistically significant differences in the diagnostic
accuracy of CgA in stratified analyses for PPI use.
Octreoscans were performed in 59 patients and were
often performed to exclude metastatic disease in patients
Figure 2. ROC curves of tumor markers for pNET with scatter plots of the observed results of tumor marker levels for individual patients with and
without pNET.

































































Abbreviation: n.d., not determined.
a With 95% CI.
b In the CgA analyses patients with lung, thymic, and gastric NET were excluded.
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previouslydiagnosedwithpNET(2).Octreoscans showed
pancreatic uptake in 23 patients, and 21 had previously
been diagnosed with pNET on conventional imaging. PP
and glucagon had greater accuracy for pNETs positive on
octreoscan, PP (AUC 0.79; 95% CI 0.63–0.96), and glu-
cagon (AUC 0.81; 95%CI 0.63–0.98). There was no dif-
ference in the accuracy of CgA for lesions positive on oc-
treoscans compared with other modalities of imaging.
In 51 patients pNET was diagnosed using EUS. EUS
was followed by FNA in 9 cases. FNA was positive for
pNET in seven patients. In the other two patients, samples
obtained by FNA were not representative.
Discussion
In this study the accuracy of CgA, PP, and glucagon for
diagnosing pNET inMEN1 patients in daily clinical prac-
tice was low. In clinical practice, tumor markers for diag-
nosing pNET are often measured simultaneously. Our re-
sults showed, that even if the three tumor markers are
measured in combination, the diagnostic accuracy can be
judged to be insufficient for diagnostic use. In a stratified
analysis, the tumormarkers did not perform better in sub-
groups based on age, tumor size, number of pNETs, and
type of imaging. For the assessment of metastatic disease,
Figure 3. Scatter plots with fitted regression lines showing the correlation between tumor marker levels and tumor size, tumor number, and age.
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AUCs were slightly higher. PP and glucagon showed
higher diagnostic accuracy for pNETs positive on octreos-
cans; however, these results should be interpreted cau-
tiously because octreoscans were performed in a selected
group of patients who had already been diagnosed with
pNET previously.
Strengths and limitations
To our knowledge, this study is the first to assess the diag-
nostic accuracy of tumormarker for pNET in a large cohort of
MEN1patients.For theDMSGdatabase,wecollectedthedata
of 90% of the total MEN1 patient population, and this data-
base is thereforeatruepopulation-baseddatabase,reducingthe
chance of selection bias.
The prevalence of pNET in our study population was
comparable with that in otherMEN1 cohorts; thus, our
results seem generalizable (23, 24). Results on the di-
agnostic accuracy of tumor markers were also consis-
tent in multiple stratified analyses, suggesting a low risk
of bias.
A few limitations should be discussed. First, pathology
is the preferred reference standard but often not available.
In patients lacking pathology, we used the results ofMRI,
CT, andEUSas the reference standard.Theuse ofmultiple
reference testsmight overestimate the diagnostic accuracy
of tumor makers (25). Diagnostic accuracy might further
be overestimated because the imaging studies and tumor
maker assessmentswereperformed in the courseofpatient
care and were not blinded or standardized. To reduce the
impact of these limitations, we required positive or neg-
ative imaging tests to be confirmed by at least one con-
secutive test in the course of follow-up. In thismanner, the
consistency of imaging results was part of the reference
standard, thereby reducing the chance of false-negative or
false-positive findings. Furthermore, we used imaging re-
sults only from 2008 onward because the accuracy of ra-
diological and EUS examinations have improved in recent
years,witha sensitivityof93%anda specificityup to95%
(26). Importantly, despite these limitations that can lead to
overestimating diagnostic accuracy, the diagnostic value
of all three markers was low in all analyses.
Another limitation is that numbers, especially for sub-
group analyses, were rather small, leading to imprecise
estimates of diagnostic test performance. This imprecision
is captured in the limits of theCI.To circumvent the power
problem inherent to binary data, we also performed an
analysis based on linear models, regressing tumor marker
levels and predictive values such as age and tumor size
(after logarithmic transformation).
The diagnostic value of the three combined tumor
markers might have been underestimated in our assess-
ment because only one or two tumor markers were as-
sessed in many patients.
The use of standard reference values as currently used
in daily clinical practice instead of age-adjusted reference
values seems justified because diagnostic accuracy did not



















CgA, g/Lb 0.42 (0.27–0.58) 0.51 (0.35–0.67) 0.44 (0.27–0.61) 0.51 (0.36–0.66) 0.41 (0.23–0.58) 0.51 (0.30–0.74)
Glucagon, ng/L 0.56 (0.42–0.70) 0.60 (0.45–0.75) 0.60 (0.44–0.76) 0.57 (0.44–0.70) 0.64 (0.48–0.81) 0.54 (0.36–0.72)
PP, pmol/L 0.57 (0.41–0.73) 0.70 (0.54–0.86) 0.58 (0.39–0.76) 0.67 (0.52–0.82) 0.64 (0.46–0.82) 0.61 (0.39–0.83)
Median tumor size was 13 mm; median tumor number was 2; and the median age was 44 years.
a With 95% CI.
b In the CgA analyses patients with lung, thymic, and gastric NET were excluded.
Table 4. Accuracy of the Tumor Markers for Diagnosis of pNET Categorized for Modality of Imaging
Tumor Marker CT AUCa MRI AUCa EUS AUCa


















Abbreviation: n, number of patients.
a With 95% CI.
b In the CgA analyses patients with lung, thymic, and gastric NET were excluded.
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improve in the sensitivity analyses using age-adjusted ref-
erence values.
Biochemical testing of gastrin, vasoactive intestinal
peptide, glucose, insulin, andC-peptide has also been sug-
gested in the diagnosis of pNET (2). We did not assess the
diagnostic accuracy of these tests for the following rea-
sons: fasting glucose, C-peptide, and insulinwere assessed
when insulinoma was suspected based on clinical symp-
toms, and high levels of gastrin can also originate from
submucosal duodenal gastrinomas, which cannot be de-
tected reliably on conventional imaging such as MRI and
CT scans. Vasoactive intestinal peptide seldom was as-
sessed in our population.
Comparison with other literature
In previous studies elevated levels of CgA were specific
for identifying neuroendocrine tumors when non-MEN1
patients were compared with healthy controls, but sensi-
tivity was variable (11, 12, 26, 27). A few small studies
already suggested that sensitivity and specificity might be
lower inMEN1 patients (14, 15). However, in these stud-
ies there was a possible selection bias, and criteria for
diagnosing pNET were often not clearly described. Our
findings in a relatively large and less biased patient sample
now show that the AUCs of the tumor markers for diag-
nosing pNET in MEN1 patients were low. The accuracy
of tumor markers for diagnosing patients with metastatic
disease was slightly higher but still low. These finding are
in line with a recent study of 115 patient with gastroen-
teropancreaticNET, inwhich the tumormarkersCgAand
PP were of limited value in diagnosing metastatic disease
(28). In this study, only seven MEN1 patients were
included.
Clinical implications
Tumormakers are of lowdiagnostic value for detecting
pNET in MEN1 patients. Therefore, we think that imag-
ing should be the preferredmethodof screening for pNET.
In times of evidence-based and cost-effective care, it is
questionable whether tumormarkers must be used for the
periodic assessment of MEN1 patients for diagnosing
pNET.The annual costs of themeasurements of the tumor
markers CgA, PP, and glucagon are estimated at approx-
imately € 110 per patient, according to the 2004 price list
of the Dutch Health Care Insurance Board. The costs of
imaging are approximately €130 for CT and €180 for
MRI, leading to annual costs of €65-€90 when these are
performed once per 2 years, respectively. However, one
study suggested that once a tumor is identified, these bio-
chemical markers, if elevated, can possibly be useful in the
follow-up of the treatment effect (29).
Conclusions
The value of CgA, PP, and glucagon for diagnosing pNET
in MEN1 patients is low. Longitudinal studies are now
needed to examine the value of CgA, glucagon, and PP as
markers in the follow-up of MEN1 patients with pNET.
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